Overview

Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease

Status:
NOT_YET_RECRUITING
Trial end date:
2029-01-01
Target enrollment:
Participant gender:
Summary
Efficacy of Mirikizumab to achieve transmural healing in patients with Crohn's Disease
Phase:
PHASE4
Details
Lead Sponsor:
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives